{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:14055"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:14055","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Mycobacterial drug target deconvolution using computational, genetic, phenotypic and proteomic approaches","abstract":"Mycobacterium tuberculosis has burdened humanity for centuries, remains one of the largest global killers, and causes over ten million tuberculosis infections yearly. Resistance to the current treatment regimen is growing and new treatment options are required. Work was undertaken to target the essential M. tuberculosis protein, AroB, and study the mechanism of action of a recently discovered antimycobacterial compound, vanoxerine (GBR12909). Several tools were developed to allow the rapid screening of potential inhibitors against the AroB protein, including biochemical, biophysical, and in vitro assays. Computational screening identified potential inhibitors of AroB, however, no compounds showed activity in vitro or in vivo against AroB or mycobacteria. In contrast, screening a drug repurposing library identified the antimycobacterial activity of vanoxerine, but no known target. Previous work suggested vanoxerine targeted AroB, however, this work has demonstrated it is not the target. Evidence provided herein highlights vanoxerine is a disruptor of the membrane electric potential, with downstream inhibition of efflux and membrane transport. A more potent analogue of vanoxerine was also developed, retaining its mechanism of action, but possessing lower activity against the known human target. Vanoxerine also targeted the pathogenic Enterococcus faecium, suggesting routes for future development against multiple pathogenic species. Overall, this work provides a strong foundation for future drug discovery studies targeting M. tuberculosis.","abstract_html":"Mycobacterium tuberculosis has burdened humanity for centuries, remains one of the largest global killers, and causes over ten million tuberculosis infections yearly. Resistance to the current treatment regimen is growing and new treatment options are required. Work was undertaken to target the essential M. tuberculosis protein, AroB, and study the mechanism of action of a recently discovered antimycobacterial compound, vanoxerine (GBR12909). Several tools were developed to allow the rapid screening of potential inhibitors against the AroB protein, including biochemical, biophysical, and in vitro assays. Computational screening identified potential inhibitors of AroB, however, no compounds showed activity in vitro or in vivo against AroB or mycobacteria. In contrast, screening a drug repurposing library identified the antimycobacterial activity of vanoxerine, but no known target. Previous work suggested vanoxerine targeted AroB, however, this work has demonstrated it is not the target. Evidence provided herein highlights vanoxerine is a disruptor of the membrane electric potential, with downstream inhibition of efflux and membrane transport. A more potent analogue of vanoxerine was also developed, retaining its mechanism of action, but possessing lower activity against the known human target. Vanoxerine also targeted the pathogenic Enterococcus faecium, suggesting routes for future development against multiple pathogenic species. Overall, this work provides a strong foundation for future drug discovery studies targeting M. tuberculosis.","abstract_has_math":false,"creators":["Kingdon, Alexander David Harry"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2023,"date_issued":"2023-12","date_published":"2023-12","updated_at":"2026-11-19T09:32:30Z","subjects":["Q Science (General)","QH301 Biology","QR Microbiology"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.grantnumber","label":"Dc Identifier Grantnumber","values":["Wellcome Trust Doctoral Training Program Antimicrobials and Antimicrobial Resistance","108876/B/15/Z"],"render_values":[{"text":"Wellcome Trust Doctoral Training Program Antimicrobials and Antimicrobial Resistance","href":null,"code":true},{"text":"108876/B/15/Z","href":null,"code":true}]}],"person_identifier_entries":[{"key":"person:identifier.orcid","label":"ORCID","values":["0000000170746893"],"render_values":[{"text":"0000-0001-7074-6893","href":"https://orcid.org/0000-0001-7074-6893","code":true}]}]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/14055/7/Kingdon2023PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A14055","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["wellcome_trust"]},{"key":"dc:creator","label":"Author","values":["Kingdon, Alexander David Harry"]},{"key":"person:identifier.orcid","label":"ORCID","values":["0000000170746893"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2023-12-04"]},{"key":"dc:date.issued","label":"Date","values":["2023-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Life & Environmental Sciences","School of Biosciences"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/14055/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Q Science (General)","QH301 Biology","QR Microbiology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.grantnumber","label":"Dc Identifier Grantnumber","values":["Wellcome Trust Doctoral Training Program Antimicrobials and Antimicrobial Resistance","108876/B/15/Z"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/14055/7/Kingdon2023PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Mycobacterium tuberculosis has burdened humanity for centuries, remains one of the largest global killers, and causes over ten million tuberculosis infections yearly. Resistance to the current treatment regimen is growing and new treatment options are required. Work was undertaken to target the essential M. tuberculosis protein, AroB, and study the mechanism of action of a recently discovered antimycobacterial compound, vanoxerine (GBR12909). Several tools were developed to allow the rapid screening of potential inhibitors against the AroB protein, including biochemical, biophysical, and in vitro assays. Computational screening identified potential inhibitors of AroB, however, no compounds showed activity in vitro or in vivo against AroB or mycobacteria. In contrast, screening a drug repurposing library identified the antimycobacterial activity of vanoxerine, but no known target. Previous work suggested vanoxerine targeted AroB, however, this work has demonstrated it is not the target. Evidence provided herein highlights vanoxerine is a disruptor of the membrane electric potential, with downstream inhibition of efflux and membrane transport. A more potent analogue of vanoxerine was also developed, retaining its mechanism of action, but possessing lower activity against the known human target. Vanoxerine also targeted the pathogenic Enterococcus faecium, suggesting routes for future development against multiple pathogenic species. Overall, this work provides a strong foundation for future drug discovery studies targeting M. tuberculosis."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Mycobacterial drug target deconvolution using computational, genetic, phenotypic and proteomic approaches"]}]}],"canonical_facts":{"dc:contributor.sponsor":["wellcome_trust"],"dc:creator":["Kingdon, Alexander David Harry"],"dc:date":["2023-12-04"],"dc:date.issued":["2023-12"],"dc:description.abstract":["Mycobacterium tuberculosis has burdened humanity for centuries, remains one of the largest global killers, and causes over ten million tuberculosis infections yearly. Resistance to the current treatment regimen is growing and new treatment options are required. Work was undertaken to target the essential M. tuberculosis protein, AroB, and study the mechanism of action of a recently discovered antimycobacterial compound, vanoxerine (GBR12909). Several tools were developed to allow the rapid screening of potential inhibitors against the AroB protein, including biochemical, biophysical, and in vitro assays. Computational screening identified potential inhibitors of AroB, however, no compounds showed activity in vitro or in vivo against AroB or mycobacteria. In contrast, screening a drug repurposing library identified the antimycobacterial activity of vanoxerine, but no known target. Previous work suggested vanoxerine targeted AroB, however, this work has demonstrated it is not the target. Evidence provided herein highlights vanoxerine is a disruptor of the membrane electric potential, with downstream inhibition of efflux and membrane transport. A more potent analogue of vanoxerine was also developed, retaining its mechanism of action, but possessing lower activity against the known human target. Vanoxerine also targeted the pathogenic Enterococcus faecium, suggesting routes for future development against multiple pathogenic species. Overall, this work provides a strong foundation for future drug discovery studies targeting M. tuberculosis."],"dc:format":["text"],"dc:identifier.grantnumber":["Wellcome Trust Doctoral Training Program Antimicrobials and Antimicrobial Resistance","108876/B/15/Z"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/14055/7/Kingdon2023PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Life & Environmental Sciences","School of Biosciences"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/14055/"],"dc:subject":["Q Science (General)","QH301 Biology","QR Microbiology"],"dcterms:accessrights":["public"],"dc:title":["Mycobacterial drug target deconvolution using computational, genetic, phenotypic and proteomic approaches"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"],"person:identifier.orcid":["0000000170746893"]},"updated_at":"2026-11-19T09:32:30Z"}